Katsumata M, Okudaira T, Samanta A, Clark D P, Drebin J A, Jolicoeur P, Greene M I
Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia 19104, USA.
Nat Med. 1995 Jul;1(7):644-8. doi: 10.1038/nm0795-644.
Certain strains of transgenic mice that express the rat neu oncogene (neuT) in mammary epithelial cells develop breast tumours at an average of 44 weeks of age. In this study, intraperitoneal injection of a monoclonal anti-receptor antibody specific for the rat neuT oncogene product dramatically affected tumour development in these transgenic mice in a dose-dependent manner. A significant proportion (50%) of mice, when injected with anti-receptor antibodies, did not develop tumours even after 90 weeks of age. The phosphotyrosine levels of the membrane fraction of breast tissues in the anti-receptor antibody-treated mice were almost completely abolished when a higher dose of antibodies was used. This study demonstrates, for the first time, that immunologic manipulation of an oncogene product can effectively prevent the development of tumours in a rodent transgenic model.
某些在乳腺上皮细胞中表达大鼠neu癌基因（neuT）的转基因小鼠品系，平均在44周龄时会发生乳腺肿瘤。在本研究中，腹腔注射针对大鼠neuT癌基因产物的单克隆抗受体抗体，以剂量依赖方式显著影响这些转基因小鼠的肿瘤发生。相当比例（50%）的小鼠在注射抗受体抗体后，即使到90周龄也未发生肿瘤。当使用更高剂量的抗体时，抗受体抗体处理小鼠乳腺组织膜部分的磷酸酪氨酸水平几乎完全消除。本研究首次证明，对癌基因产物进行免疫操作可有效预防啮齿动物转基因模型中的肿瘤发生。
